Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

2.780 -0.020 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,892
Open 2.760
Bid (Size) 2.790 (100)
Ask (Size) 2.900 (2,600)
Prev. Close 2.800
Today's Range 2.710 - 2.900
52wk Range 1.110 - 5.744
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
From New to The Street
Via ACCESS Newswire

Performance

YTD
-10.6%
-10.6%
1 Month
-29.3%
-29.3%
3 Month
+29.9%
+29.9%
6 Month
-5.8%
-5.8%
1 Year
-46.5%
-46.5%

More News

Read More
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street(R) to Broadcast Show #762 Tonight on Bloomberg Television at 6:30 PM ET, Featuring Envoy Medical (NASDAQ:COCH), AlphaCompute (NASDAQ:ALP), RHINO Bitcoin (OTC PINK:RHNO), and Big Sky Industrial (NASDAQ:BSIN)
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Launches AI-Powered ZetaOmics Computational Biology Platform
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
Via ACCESS Newswire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
Via ACCESS Newswire
News headline image
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Support for HARMONIC(TM) Trial Amendments in Never-Smoker NSCLC
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q1 2026 Results, Advances Clinical Pipeline and AI Commercialization Strategy
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4.4 Million Registered Direct Offering
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
From Lantern Pharma Inc.
Via Business Wire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 2.780
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 08/06/26 04:00 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 31.09M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 31M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.